This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Sipe, J. Articles by Beutler, E Search for Related Content PubMed Articles by Sipe, J. Articles by Beutler, E Social Bookmarking                         What's this?

Development of cladribine treatment in multiple sclerosis

Department of Molecular and Experimental Medicine, The Scripps Research Institute and the Divisions of Neurology and Radiology, Scripps Clinic and Research Foundation, La folia, California, USA

JS Romine

Department of Molecular and Experimental Medicine, The Scripps Research Institute and the Divisions of Neurology and Radiology, Scripps Clinic and Research Foundation, La folia, California, USA

JA Koziol

Department of Molecular and Experimental Medicine, The Scripps Research Institute and the Divisions of Neurology and Radiology, Scripps Clinic and Research Foundation, La folia, California, USA

R McMillan

Department of Molecular and Experimental Medicine, The Scripps Research Institute and the Divisions of Neurology and Radiology, Scripps Clinic and Research Foundation, La folia, California, USA

J Zyroff

Department of Molecular and Experimental Medicine, The Scripps Research Institute and the Divisions of Neurology and Radiology, Scripps Clinic and Research Foundation, La folia, California, USA

E Beutler

Department of Molecular and Experimental Medicine, The Scripps Research Institute and the Divisions of Neurology and Radiology, Scripps Clinic and Research Foundation, La folia, California, USA

Cladribine is a new type of drug with properties of selective lymphocyte suppression that appear to favorably alter the clinical course of progressive multiple sclerosis (MS). The history of the development of cladribine treatment in chronic progressive MS is discussed, and the application of cladribine treatment to progressive multiple sclerosis in a double-blind, placebo crossover study is reviewed. Cladribine selectively targets both resting and dividing lymphocytes and may be able to destroy the activated lymphocytes that induce CNS demyelination, thus producing stabilization or improvement in chronic MS. Although the role of cladribine has not yet been fully defined, additional studies are underway to evaluate the efficacy and safety of cladribine in both progressive MS and relapsing-remitting MS.

Key Words: multiple sclerosis • cladribine • immunosuppression

Multiple Sclerosis, Vol. 1, No. 6, 343-347 (1996)
DOI: 10.1177/135245859600100612


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?